Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
- Conditions
- Mycobacterium Avium-intracellulare InfectionHIV Infections
- Registration Number
- NCT00002032
- Lead Sponsor
- Pharmacia
- Brief Summary
The primary objectives of this trial are: To compare the safety of oral rifabutin versus placebo in the treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200 cells/mm3. To investigate the incidence of MAC in these patients. A secondary objective is to compare clinical response, quality of life (Karnofsky), and survival between these two groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 750
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (32)
Ctr for Special Immunology
🇺🇸Fort Lauderdale, Florida, United States
Olive View Med Ctr
🇺🇸Sylmar, California, United States
Denver Public Health Dept
🇺🇸Denver, Colorado, United States
Veterans Administration Med Ctr
🇺🇸Washington, District of Columbia, United States
TheraFirst Med Ctrs Inc
🇺🇸Fort Lauderdale, Florida, United States
Mem Hosp Hollywood
🇺🇸Hollywood, Florida, United States
VP Med Services / HHCS Research Institute Inc
🇺🇸Orlando, Florida, United States
AIDS Research Consortium of Atlanta
🇺🇸Atlanta, Georgia, United States
Grady Memorial Hosp / Hughs Spalding Med Ctr
🇺🇸Atlanta, Georgia, United States
Dr Winkler Weinberg
🇺🇸Roswell, Georgia, United States
Scroll for more (22 remaining)Ctr for Special Immunology🇺🇸Fort Lauderdale, Florida, United States